MorphoSys to Present at Upcoming Investor Conferences
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
J.P. Morgan Healthcare Conference
Date: January 12, 2017, 7:30 am PST (4:30 pm CET, 3:30 pm GMT)
Venue: San Francisco, CA, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Anke Linnartz, Head of Corporate Communications & IR
Kepler Cheuvreux German Corporate Conference
Date: January 17, 2017, 4:45 pm CET (10:45 am EST, 3:45 pm GMT)
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Anke Linnartz, Head of Corporate Communications & IR
A PDF version of the presentation will be provided at www.morphosys.com. The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully
applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the
fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's
disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on
making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit http:// www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R),
Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties.
Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward- looking statements as far as the wording of the relevant press release is
concerned.
| Language: English |
| Company: MorphoSys AG |
| Semmelweisstr. 7 82152 Planegg Germany |
| Phone: +49 (0)89 899 27-0 |
| Fax: +49 (0)89 899 27-222 |
|
E-mail: investors@morphosys.com
|
|
Internet: www.morphosys.com
|
|
ISIN: DE0006632003
|
| WKN: 663200 |
| Indices: TecDAX |
| Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market
in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
For more information, please contact:
MorphoSys AG
Anke Linnartz Head of Corporate Communications & IR
or
Jochen Orlowski
Associate Director Corporate Communications & IR
or
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170103005668/en/